FDA Approval Alert: The Need-to-Know | Perioperative Durvalumab in Resectable NSCLC

In August 2024, the FDA approved neoadjuvant durvalumab plus platinum-containing chemotherapy followed by single-agent durvaumab as adjuvant treatment for patients with resectable non–small cell lung cancer who do not have a known EGFR mutation or ALK rearrangement.

Results from the phase 3 AEGEAN trial led to the approval of neoadjuvant and adjuvant durvalumab for patients with resectable NSCLC.
Perioperative Durvalumab Approved by FDA in Resectable NSCLC
Article
Aug 15, 2024 9:53 PM
Results from the phase 3 AEGEAN trial led to the approval of neoadjuvant and adjuvant durvalumab for patients with resectable NSCLC.